TDO2 and cancer: In preclinical cancer models, the IDO1/TDO inhibitor RG70099 demonstrated significant decrease Kyn levels, while reduced tumor volumes was reported in response to the IDO1/TDO inhibitor EPL-1410 when evaluated as single agent (129, 130).